The Food and Drug Administration has expanded the approved uses of somapacitan-beco (Sogroya, Novo Nordisk) to include three pediatric conditions, offering new treatment options for children with growth hormone deficiencies and related disorders. The once-weekly injectable growth hormone is now approved for children aged 2.5 years and older with idiopathic short stature, those born small for gestational age who haven’t experienced catch-up growth by age two, and those with growth failure linked to Noonan syndrome, according to a press release from Novo Nordisk.
This approval marks a significant step forward in pediatric endocrinology, providing a less frequent dosing schedule compared to traditional daily growth hormone injections. Growth hormone is a naturally occurring hormone crucial for development, and deficiencies can lead to stunted growth. Somapacitan-beco aims to address these deficiencies with a more convenient administration method, potentially improving adherence and quality of life for young patients and their families.
Understanding the Newly Approved Conditions
Idiopathic Short Stature refers to short stature without a clear medical cause. Children with this condition often fall below the typical growth curve for their age and genetic background. Small for Gestational Age (SGA) describes infants born smaller than expected for their gestational age, and even as many catch up in growth, some do not. Noonan Syndrome is a genetic disorder that can cause a variety of developmental problems, including short stature and heart defects. The Mayo Clinic provides further information on Noonan Syndrome.
REAL8 Study Results Support Approval
The FDA’s decision was based on data from the REAL8 study, which demonstrated that somapacitan-beco, administered weekly at doses of 5mg, 10mg, or 15mg, was noninferior to daily growth hormone treatment in terms of annualized height velocity over one year. This means the weekly injection performed as well as the standard daily treatment in promoting growth in children with these conditions. The study included children with idiopathic short stature, those born small for gestational age, and those with Noonan syndrome.
How Somapacitan-Beco Works
Somapacitan-beco is a long-acting growth hormone, meaning it remains in the body for a longer period after injection compared to traditional formulations. This allows for once-weekly dosing via subcutaneous injection – an injection just under the skin. The medication replaces or supplements the body’s own growth hormone, helping to stimulate growth and development.
Expert Perspective on the New Treatment Option
“Families and health care professionals now have the option to consider a once-weekly growth hormone as treatment with 313 injection-free days per year for their children 2.5 years and older with idiopathic short stature, Noonan syndrome and born small for gestational age,” said Aristides Maniatis, MD, founder of Rocky Mountain Pediatric Endocrinology in Centennial, Colorado, and an investigator in the REAL8 study. “Sogroya is an effective alternative to daily injections that supports children’s growth goals and may help fit into their routine.”
Previous Approvals and Ongoing Research
Somapacitan-beco was initially approved by the FDA for adults with growth hormone deficiency in 2020 and later for children with growth failure due to inadequate endogenous growth hormone secretion. The expansion of indications reflects ongoing research into the drug’s efficacy and safety across a broader range of patients. Healio reported on the initial approval for adult growth hormone deficiency.
The availability of a once-weekly growth hormone injection represents a significant advancement in the management of growth disorders in children. As with any medication, healthcare providers will carefully evaluate each patient’s individual needs and circumstances to determine if somapacitan-beco is the appropriate treatment option. Further research will continue to monitor the long-term effects and optimal use of this new therapy.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The FDA is expected to publish detailed prescribing information for the expanded indications on its website in the coming weeks. Parents and caregivers with questions about somapacitan-beco should consult with their child’s pediatrician or endocrinologist.
Share this article with anyone who might benefit from learning about this new treatment option for pediatric growth disorders.
